Abstract

RECENT FINDINGS IN PHARMACOTHERAPEUTICAL MANAGEMENT OF IMMUNOGLOBULIN A NEPHROPATHY: AN OVERVIEW

Shyamily John, Kannan C.?, Sambathkumar R.

ABSTRACT

IgA nephropathy (IgAN) is said to be the major etiological reason of kidney failure surrounded by 35% of the Asian Population and major type of primary glomerulonephritis in Europeans and is characterized by many clinical and pathological features which may fluctuate from one person to other.. It is predicted that IgAN is the most common type of renal disease and 20-40% of the people who have IgAN are prone to develop end-stage renal disease, in which they will need to have kidney transplantation or Dialysis to survive. The treatment for IgAN we mentioned in the article is only for adults. No optimal treatment is issued for those individuals living with this disease. The current management depends up on the presence of proteinuria, blood pressure, estimated Glomerular Filtration Rate (eGFR) and various pathological features, including anti-proteinuric and antihypertensive therapy, corticosteroids, immunosuppressive agents, fish oil and tonsillectomy. The pharmacotherapeutic treatment of IgAN is issued in this article based on these criteria.

Keywords: Immunoglobulin A Nephropathy, IgAN, Glomerulonephritis, Corticosteroids.